Adam Cotton is a GentiBio Board Observer and an Associate at the Novartis Venture Fund (NVF). In addition to GentiBio, he is a Board Observer at Mediar Therapeutics and three other stealth-mode companies. Prior to joining NVF, his PhD research in the labs of Jim Wells and Ian Seiple on antibody-engineering led to Epi Biologics where he is a scientific co-founder. Additionally, he worked on early strategy and program prioritization in one of RA Capital’s incubator companies and helped transition Rezo Therapeutics out of the Krogan/ Shokat labs. Adam holds a BA in Chemistry from Harvard University, an MBA from the University of New Mexico, and a PhD in Chemistry and Chemical Biology from the University of California, San Francisco.
Adam Cotton, PhD, MBA
Associate, Novartis Venture Fund (NVF), Board Observer
